Hormone therapy after endometrial cancer.
Endometrial carcinoma is listed under the absolute contraindications to hormone therapy (HT). According to current opinion, HT after stage I or II is still considered an option, and continuous combined oestrogen/progestogen replacement therapy (CCEPT) would be recommended. However, up to now, only observational studies have been put forward. Although none of these studies have established an increased rate of recurrence or mortality, alternatives such as phytopreparations and tibolone, or particular psychotherapeutic drugs, such as venlafaxine, should be considered for the relief of climacteric complaints. Progestogen-only therapy (PT) particularly has been considered. However, the currently discussed possible progestogen effects regarding an increased risk of breast cancer have to be taken into account. Indeed, the wider discussion about the gestagen effects regarding the risk of breast cancer is to be considered. Generally, after hysterectomy, at least for patients with cardiovascular risk factors, the preference today is to use low-dose oestrogen therapy (patches or gels) instead of CCEPT, and this is also now recommended for patients after endometrial cancer. This is to be noted because of the risk factors for endometrial carcinoma, such as hypertension, obesity, polycystic ovary syndrome (PCO) and diabetes mellitus. However, each form of HT should be only exceptionally recommended, and the patients must be informed about the risks that exist and the use of alternatives.
Mueck
A O
AO
Section of Endocrinology and Menopause, Women's University Hospital, Tuebingen, Germany. endo.meno@med.uni-tuebingen.de
Seeger
H
H
D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004967:Estrogens / Q000172:deficiency; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D011374:Progesterone / Q000172:deficiency
D004967:Estrogens; D011374:Progesterone